Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis.pdf (693.41 kB)
Download file

Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis.

Download (693.41 kB)
journal contribution
posted on 20.06.2019, 12:56 by MM Lalu, DA Fergusson, W Cheng, MT Avey, D Corbett, D Dowlatshahi, MR Macleod, ES Sena, D Moher, R Shorr, SK McCann, LJ Gray, MD Hill, A O'Connor, K Thayer, F Haggar, A Dobriyal, HS Chung, NJ Welton, B Hutton
Introduction: Globally, stroke is the second leading cause of death. Despite the burden of illness and death, few acute interventions are available to patients with ischemic stroke. Over 1,000 potential neuroprotective therapeutics have been evaluated in preclinical models. It is important to use robust evidence synthesis methods to appropriately assess which therapies should be translated to the clinical setting for evaluation in human studies. This protocol details planned methods to conduct a systematic review to identify and appraise eligible studies and to use a network meta-analysis to synthesize available evidence to answer the following questions: in preclinical in vivo models of focal ischemic stroke, what are the relative benefits of competing therapies tested in combination with the gold standard treatment alteplase in (i) reducing cerebral infarction size, and (ii) improving neurobehavioural outcomes? Methods: We will search Ovid Medline and Embase for articles on the effects of combination therapies with alteplase. Controlled comparison studies of preclinical in vivo models of experimentally induced focal ischemia testing the efficacy of therapies with alteplase versus alteplase alone will be identified. Outcomes to be extracted include infarct size (primary outcome) and neurobehavioural measures. Risk of bias and construct validity will be assessed using tools appropriate for preclinical studies. Here we describe steps undertaken to perform preclinical network meta-analysis to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. This will be a novel use of this evidence synthesis approach in stroke medicine to assess pre-clinical therapeutics. Combining all evidence to simultaneously compare mutliple therapuetics tested preclinically may provide a rationale for the clinical translation of therapeutics for patients with ischemic stroke.  Dissemination: Review findings will be submitted to a peer-reviewed journal and presented at relevant scientific meetings to promote knowledge transfer. Registration: PROSPERO number to be submitted following peer review.

Funding

This work was supported by Canadian Institutes of Health Research (Grant #365473). M.M.L. is supported by The Ottawa Hospital Anesthesia Alternate Funds Association and the Scholarship Protected Time Program, Department of Anesthesiology and Pain Medicine, uOttawa. D.M. is supported by a University Research Chair. N.J.W. was supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol.

History

Citation

F1000Research, 2019, 8:11

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences

Version

VoR (Version of Record)

Published in

F1000Research

Publisher

F1000Research

eissn

2046-1402

Acceptance date

08/08/2018

Copyright date

2019

Available date

20/06/2019

Publisher version

https://f1000research.com/articles/8-11/v1

Notes

Supplementary materials Supplementary File 1. PRISMA-Protocols checklist. https://f1000researchdata.s3.amazonaws.com/supplementary/15869/3ee77965-a723-42e4-8329-ea51c97b1090.docx Supplementary File 2. Representative search strategy. https://f1000researchdata.s3.amazonaws.com/supplementary/15869/1109c6ba-360b-4484-b8b4-e8f4797d5fc6.docx

Language

en